5 Best Performing Small Cap Stocks So Far in 2026

3. Climb Bio Inc (NASDAQ:CLYM)

Climb Bio Inc (NASDAQ:CLYM) is one of the best performing small cap stocks so far in 2026. Oppenheimer lifted the price target on Climb Bio Inc (NASDAQ:CLYM) to $18 from $10 on April 12, maintaining an Outperform rating on the shares. The rating update came ahead of the upcoming clinical reveals, which will reveal how subcutaneous budoprutug, as well as CLYM116, perform in healthy volunteers. Oppenheimer’s model had not previously included any value for ‘116, in development for IgA nephropathy, and yet the firm views it as exciting as budoprutug, perhaps more so.

Climb Bio Inc (NASDAQ:CLYM) also received a rating update from Mizuho on April 15. The firm initiated coverage of the stock with an Outperform rating and set an $18 price target. It told investors in a research note that the company’s lead assets, budoprutug and CLYM116, are positioned to establish a “compelling B-cell targeting pipeline with best-in-indication profiles in autoimmune nephropathies”. Mizuho believes that Climb Bio Inc’s (NASDAQ:CLYM) updates for budoprutug in primary membranous nephropathy in H2 2026, along with initial data for CLYM116 in healthy volunteers in mid-2026, can offer data points that will “validate potential to drive the deepest reductions in proteinuria within their competitive landscapes”.

Climb Bio Inc (NASDAQ:CLYM) is a clinical-stage biotechnology company that develops therapeutics for patients with immune-mediated diseases. The company’s lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases.